Effectiveness of MF59™-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly

Abstract Annual circulation of influenza virus coincides with a peak in cardiovascular and pneumonia mortality/morbidity. This study aimed to determine the effectiveness of MF59™-adjuvanted subunit influenza vaccine in preventing hospitalisation due to acute coronary syndrome (ACS), cerebrovascular...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2007-10, Vol.25 (42), p.7313-7321
Main Authors: Puig-Barberà, Joan, Díez-Domingo, Javier, Varea, Ángel Belenguer, Chavarri, Germán Schwarz, Rodrigo, José A. Lluch, Hoyos, Santiago Pérez, Vidal, David González
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Aged
Aged, 80 and over
Allergy and Immunology
Applied microbiology
Biological and medical sciences
Cardiovascular diseases
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - prevention & control
Case-Control Studies
Cerebrovascular disorders
Cerebrovascular Disorders - epidemiology
Cerebrovascular Disorders - prevention & control
Elderly
Fundamental and applied biological sciences. Psychology
Heart attacks
Hospitalization
Hospitals
Humans
Influenza
Influenza Vaccines - administration & dosage
Influenza virus
Mass Vaccination - statistics & numerical data
MF59™-adjuvanted subunit influenza vaccine
Microbiology
Mortality
Older people
Pneumonia
Pneumonia - epidemiology
Pneumonia - prevention & control
Polysorbates - administration & dosage
Risk Factors
Spain - epidemiology
Squalene - administration & dosage
Studies
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Subunit - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Annual circulation of influenza virus coincides with a peak in cardiovascular and pneumonia mortality/morbidity. This study aimed to determine the effectiveness of MF59™-adjuvanted subunit influenza vaccine in preventing hospitalisation due to acute coronary syndrome (ACS), cerebrovascular accident (CVA) and pneumonia in the elderly. Three case–control studies were performed during the 2004–2005 influenza season in three health districts in Valencia, Spain (total elderly [>64 years of age] population: n = 105,454). Controls were patients admitted for an acute surgical process or trauma within 10 days of case admission. In total, 159 patients were hospitalised for ACS, 148 for CVA and 242 for pneumonia. The risk of hospitalisation after the start of the influenza season was significantly lower in vaccinated patients compared with non-vaccinated patients (adjusted odds ratios: 0.13 [ P = 0.013] for ACS; 0.07 [ P = 0.007] for CVA; 0.31 [ P = 0.005] for pneumonia). During peak virus circulation, vaccination with MF59™-adjuvanted subunit influenza vaccine was associated with an 87% relative risk reduction in hospitalisation for ACS, 93% for CVA, and 69% for pneumonia.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2007.08.039